Patient Accessibility and Budget Impact of Orphan Drugs in South Korea: Long-Term and Real-World Data Analysis (2007-2019)
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Se Hee | - |
dc.contributor.author | Yoo, Seung-Lai | - |
dc.contributor.author | Bang, Joon Seok | - |
dc.contributor.author | Lee, Jong Hyuk | - |
dc.date.available | 2021-02-22T05:35:25Z | - |
dc.date.issued | 2020-05 | - |
dc.identifier.issn | 1661-7827 | - |
dc.identifier.issn | 1660-4601 | - |
dc.identifier.uri | https://scholarworks.sookmyung.ac.kr/handle/2020.sw.sookmyung/2457 | - |
dc.description.abstract | This study aimed to identify orphan drug accessibility and impact on pharmaceutical budgets in South Korea by analyzing the status of orphan drug designation, approval, reimbursement, and pharmaceutical expenditure. We analyzed the dataset on orphan drugs designated, approved, and reimbursed from 2007 to 2019 based on long-term real-world data. The designated and approved orphan drugs were 165 and 156, respectively, and 88 out of 156 approved products were reimbursed. Total expenditure on orphan drugs increased annually to account for about 1.44% of total pharmaceutical expenditure in 2018. Orphan drug expenditure per patient increased on average by 8.7% per year. The average annual cost of orphan drugs was USD 27,000-USD 47,000, with the maximum value of USD 260,000-USD 560,000. As there are a number of orphan drugs that have not yet been reimbursable after approval, a reimbursement policy should be established that considers the characteristics of orphan drugs. Since the rapid increase in orphan drug expenditure can be a potential threat to the insurance budget, budget management should also be considered. In conclusion, it is necessary to take preemptive measures to manage the health insurance budget efficiently while improving patient accessibility to orphan drugs. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | MDPI | - |
dc.title | Patient Accessibility and Budget Impact of Orphan Drugs in South Korea: Long-Term and Real-World Data Analysis (2007-2019) | - |
dc.type | Article | - |
dc.publisher.location | 스위스 | - |
dc.identifier.doi | 10.3390/ijerph17092991 | - |
dc.identifier.scopusid | 2-s2.0-85084038986 | - |
dc.identifier.wosid | 000535745400015 | - |
dc.identifier.bibliographicCitation | INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, v.17, no.9 | - |
dc.citation.title | INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH | - |
dc.citation.volume | 17 | - |
dc.citation.number | 9 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | ssci | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Environmental Sciences & Ecology | - |
dc.relation.journalResearchArea | Public, Environmental & Occupational Health | - |
dc.relation.journalWebOfScienceCategory | Environmental Sciences | - |
dc.relation.journalWebOfScienceCategory | Public, Environmental & Occupational Health | - |
dc.subject.keywordPlus | ACCESS | - |
dc.subject.keywordPlus | EXPENDITURE | - |
dc.subject.keywordAuthor | Orphan drug | - |
dc.subject.keywordAuthor | rare disease | - |
dc.subject.keywordAuthor | pharmaceutical expenditure | - |
dc.subject.keywordAuthor | reimbursement | - |
dc.subject.keywordAuthor | budget impact | - |
dc.subject.keywordAuthor | budget controls | - |
dc.subject.keywordAuthor | patient accessibility | - |
dc.subject.keywordAuthor | health services accessibility | - |
dc.identifier.url | https://www.mdpi.com/1660-4601/17/9/2991 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
Sookmyung Women's University. Cheongpa-ro 47-gil 100 (Cheongpa-dong 2ga), Yongsan-gu, Seoul, 04310, Korea02-710-9127
Copyright©Sookmyung Women's University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.